bluebird bio
BLUE
BLUE was delisted on the 30th of May, 2025.
247 hedge funds and large institutions have $2.7B invested in bluebird bio in 2020 Q1 according to their latest regulatory filings, with 30 funds opening new positions, 95 increasing their positions, 76 reducing their positions, and 55 closing their positions.
25% more repeat investments, than reductions
Existing positions increased: 95 | Existing positions reduced: 76
0% more funds holding in top 10
Funds holding in top 10: 3 → 3 (0)
3.44% less ownership
Funds ownership: 108.65% → 105.21% (-3.4%)
10% less funds holding
Funds holding: 274 → 247 (-27)
31% less call options, than puts
Call options by funds: $24.2M | Put options by funds: $35.1M
45% less first-time investments, than exits
New positions opened: 30 | Existing positions closed: 55
49% less capital invested
Capital invested by funds: $5.27B → $2.7B (-$2.57B)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
+$83.3M |
| 2 |
Adage Capital Partners
Boston,
Massachusetts
|
+$76.8M |
| 3 |
PIM
Platinum Investment Management
Sydney Australia 2000,
Australia
|
+$34.1M |
| 4 |
AC
Armistice Capital
New York
|
+$23.5M |
| 5 |
Citadel Advisors
Miami,
Florida
|
+$20.5M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$184M |
| 2 |
Capital World Investors
Los Angeles,
California
|
-$69.7M |
| 3 |
Wellington Management Group
Boston,
Massachusetts
|
-$49.5M |
| 4 |
Capital International Investors
Los Angeles,
California
|
-$48.1M |
| 5 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$26.6M |
BLUE Hedge Fund Activity: Q1 2020 in Review
247 of the 4,547 institutional investors tracked by Wall St. Rank reported a position in bluebird bio (BLUE) for Q1 2020, worth a combined $2.7B — down 49% from $5.27B a quarter earlier.
Sellers outnumbered buyers: 55 funds closed out of BLUE and 30 opened new positions — a net loss of 25 holders — while 76 trimmed existing stakes and 95 added.
The largest buyer was Royal Bank of Canada, adding an estimated $83.3M. The largest seller was Fidelity Investments, cutting an estimated $184M.
- 247 institutional investors held bluebird bio (BLUE) as of Q1 2020, down from 274 in Q4 2019.
- Funds reported $2.7B of bluebird bio stock for Q1 2020, down 49% quarter-over-quarter.
- 30 funds opened new bluebird bio positions in Q1 2020 and 55 closed out, a net change of -25 holders.
- The largest bluebird bio buyer in Q1 2020 was Royal Bank of Canada, an estimated $83.3M added.
- The largest bluebird bio seller in Q1 2020 was Fidelity Investments, an estimated $184M sold.
Based on aggregated 13F filings for Q1 2020.